Yttrium Y 90 anti-CD45 monoclonal antibody BC8 (Fred Hutchinson Cancer Research Center)

N/A

Report date: 2025/09/12 17:58:40

Base Information

Drug NameYttrium Y 90 anti-CD45 monoclonal antibody BC8 (Fred Hutchinson Cancer Research Center)
Drug Alias Name90Y-BC8-DOTA
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agent +[5] 
Mechanisms of ActionAnti-CD45Ionising radiation emitters
TargetsLeukocyte common antigen
Therapy Area/IndicationsAngioimmunoblastic T-cell LymphomaWaldenstrom MacroglobulinemiaMultiple Myeloma +[28] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFred Hutchinson Cancer Research Center
Active IndicationsN/A
Inactive IndicationsAngioimmunoblastic T-cell LymphomaWaldenstrom MacroglobulinemiaMultiple Myeloma +[28] 

Other Information

ATC CodeN/A
Related LinksN/A